Parkinson's disease other imaging findings

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

PET scan: In PET scan we can see that the uptake of [18F]-flurodopa tracer in reduce in the caudate and putamen in PD patients.

DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).

Sonography: In sonography of PD patient’s brain we can see hyperechogenicity of the STN.

Other Imaging Findings

PET scan: In PET scan we can see that the uptake of [18F]-flurodopa tracer in reduce in the caudate and putamen in PD patients.^[1]

18F PET scan shows decreased dopamine activity in the basal ganglia, a pattern which aids in diagnosing Parkinson’s disease.

DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).^[2]^[3]

Sonography: In sonography of PD patient’s brain we can see hyperechogenicity of the STN.^[4]

References

↑ Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (October 2010). “Typical cerebral metabolic patterns in neurodegenerative brain diseases”. Mov. Disord. 25 (14): 2395–404. doi:10.1002/mds.23291. PMID 20669302.
↑ Stoessl AJ, Martin WW, McKeown MJ, Sossi V (November 2011). “Advances in imaging in Parkinson’s disease”. Lancet Neurol. 10 (11): 987–1001. doi:10.1016/S1474-4422(11)70214-9. PMID 22014434.
↑ Kägi G, Bhatia KP, Tolosa E (January 2010). “The role of DAT-SPECT in movement disorders”. J. Neurol. Neurosurg. Psychiatry. 81 (1): 5–12. doi:10.1136/jnnp.2008.157370. PMID 20019219.
↑ Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (May 2008). “The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study”. Lancet Neurol. 7 (5): 417–24. doi:10.1016/S1474-4422(08)70067-X. PMID 18394965.

Template:WH Template:WS

[pmid20669302-1] Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (October 2010). “Typical cerebral metabolic patterns in neurodegenerative brain diseases”. Mov. Disord. 25 (14): 2395–404. doi:10.1002/mds.23291. PMID 20669302.

[pmid22014434-2] Stoessl AJ, Martin WW, McKeown MJ, Sossi V (November 2011). “Advances in imaging in Parkinson’s disease”. Lancet Neurol. 10 (11): 987–1001. doi:10.1016/S1474-4422(11)70214-9. PMID 22014434.

[pmid20019219-3] Kägi G, Bhatia KP, Tolosa E (January 2010). “The role of DAT-SPECT in movement disorders”. J. Neurol. Neurosurg. Psychiatry. 81 (1): 5–12. doi:10.1136/jnnp.2008.157370. PMID 20019219.

[pmid18394965-4] Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (May 2008). “The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study”. Lancet Neurol. 7 (5): 417–24. doi:10.1016/S1474-4422(08)70067-X. PMID 18394965.

[1]

[2]

[3]

[4]

Parkinson's disease other imaging findings

Overview

Other Imaging Findings

References

Looking for the patient version?